GlassScriptPhysician profile
Sharon S Wagamon
NPI 1811107683
$1,531.23
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $11.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $134.59 | 2019-2020 | |
| Genentech USA, INC. | $129.10 | 2019 | |
| Merck Sharp & Dohme LLC | $123.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.92 | 2019 | |
| Celgene Corporation | $100.34 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.08 | 2019 | |
| Genzyme Corporation | $62.02 | 2019 | |
| Eisai INC. | $61.94 | 2019 | |
| Amgen INC. | $59.12 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $52.42 | 2019 | |
| Lilly USA, LLC | $45.90 | 2019 | |
| Amag Pharmaceuticals, INC. | $42.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $40.05 | 2019 | |
| Janssen Biotech, INC. | $40.00 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $38.72 | 2019 | |
| Astellas Pharma US INC | $34.53 | 2019 | |
| Verastem, INC. | $34.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.16 | 2019 | |
| Exelixis INC. | $24.12 | 2019 | |
| Foundation Medicine, INC. | $21.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.27 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.87 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2019 | |
| Partner Therapeutics, INC. | $16.05 | 2019 | |
| Incyte Corporation | $15.99 | 2019 | |
| Pfizer INC. | $13.23 | 2019 | |
| Clovis Oncology, INC. | $12.81 | 2019 | |
| Tesaro, INC. | $12.37 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.36 | 2019 | |
| Puma Biotechnology, INC. | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Wagamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.